Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

ELI Lilly & Co

Make bebtelovimab commercially available for purchase

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
4 Aug 2022
Due
21 Aug 2022
Delivered
by 15 Aug 2022
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Lilly intends to make bebtelovimab commercially available for purchase by U.S. states/territories, hospitals and a broad set of other providers through a sole distributor beginning the week of Aug. 15”
  • SourceELI Lilly & Co Form 8-K press release, 2022-08-04
  • FilingSEC filing index
  • Deadline as statedbeginning the week of Aug. 15
  • Deadline used21 Aug 2022, the last day of the stated period
  • TypeProduct
  • Permanent referenceKI-C-2022-LLY-004490
    Cite as https://keptindex.org/c/KI-C-2022-LLY-004490/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company confirmed in its 10-Q filing that it made bebtelovimab commercially available for purchase by U.S. states, territories, and hospitals beginning in the third quarter of 2022.

  • A
    ELI Lilly & Co 10-Q filed 2022-11-01 Regulatory filing · published 1 Nov 2022 · retrieved 3 Oct 2026 · kept permanently by the SEC · fingerprint 1a5bbab141d2
    “Beginning in the third quarter of 2022 and in collaboration with the U.S. government, we have made bebtelovimab commercially available for purchase by U.S. states/territories, hospitals, and certain other providers.” ✓ confirmed on the page

Market reaction: the shares moved +3.8% against the S&P 500 over the three sessions around the disclosure (31 Oct 2022 to 3 Nov 2022). What this measures

Checked 3 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Product other
Indicative materiality
Low rules
Action
Make
Deliverable
bebtelovimab commercial availability
Where
U.S.
Language
Aspirational (“aims”, “intends”)
In the company’s control
High
Specificity
High
Depends on
Government

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
  4. Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2022-LLY-004490 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.